$1.39
-0.01 (-0.71%)
Open$1.39
Previous Close$1.40
Day High$1.43
Day Low$1.35
52W High$2.35
52W Low$0.77
Volume—
Avg Volume67.8K
Market Cap22.12M
P/E Ratio—
EPS$-0.72
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+2,243.9% upside
Current
$1.39
$1.39
Target
$32.58
$32.58
$17.80
$32.58 avg
$40.39
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 357.4K | 2.19M | 1.96M |
| Net Income | -12,517,923 | -647,190 | -493,473 |
| Profit Margin | -3,509.7% | -29.6% | -25.2% |
| EBITDA | -14,048,408 | -712,204 | -583,546 |
| Free Cash Flow | — | -781,686 | -525,232 |
| Rev Growth | — | +18.0% | +10.8% |
| Debt/Equity | 0.14 | 0.28 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.68 | -0.45% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $412.84 | -1.20% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.12 | -0.01% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $508.33 | -1.57% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.64 | -0.29% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $227.29 | +0.07% | 35.2 | 28.41B |